$Novo-Nordisk A/S(NVO)$ has made remarkable strides by integrating AI into the drafting of regulatory drug documents. By utilizing Claude, they've reduced the time to draft clinical research reports from around 15 weeks to less than 10 minutes—an incredible leap in efficiency!
What's even more impressive is that tasks that once required over 50 writers can now be completed by just 3 people with the help of Claude, all while spending less than the salary of one traditional writer.
The introduction of AI has drastically lowered costs and enhanced accuracy, marking a major milestone in the future of the healthcare industry!
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments